期刊文献+

氮杂吲哚类PARP-1抑制剂的合成及活性评价 被引量:6

Synthesis and activity evaluation of PARP-1 inhibitors with azaindole skeleton
原文传递
导出
摘要 PARP-1通过催化ADP-核糖单元(ADP-ribose)从烟酰胺腺嘌呤二核苷酸(nicotinamide adenine dinucleotide,NAD+)转移至各种底物蛋白上,参与损伤DNA的修复过程,是潜在的新机制的抗肿瘤药物靶标。本文设计合成了新结构氮杂吲哚类目标化合物16个,获得了对PARP-1具有抑制活性的化合物8个,其中2-位为脂环胺取代的氮杂吲哚对PARP-1和PARP-2均有抑制活性。 PARP [poly(ADP-ribose)polymerase] represents a novel potential target in cancer therapy. It is involved in a DNA repair process by catalyzing the transfer of ADP-ribose units from NAD ~ to a number of its substrate proteins. In this work, a series of novel azaindole derivatives was designed and synthesized. Moreover, 16 target molecules were screened and 8 compounds displayed inhibitory activity against PARP-1. It has been demonstrated that these azaindoles bearing cycloamine substituents at 2-position were active to both PARP-1 and PARP-2.
出处 《药学学报》 CAS CSCD 北大核心 2013年第12期1792-1799,共8页 Acta Pharmaceutica Sinica
基金 中国医学科学院、北京协和医学院药物研究所基本科研业务费资助项目(2013CHX16)
关键词 PARP-1 抑制剂 氮杂吲哚 抗肿瘤药物 PARP-1 inhibitor azaindole antitumor agent
  • 相关文献

参考文献1

二级参考文献14

  • 1Lucio T,Ilaria P,Grazia G.Potential clinical applications of poly(ADP-Ribose) polymerase (PARP) inhibitors[J].Pharmacol Res,2002,45:73-85.
  • 2Ha HC,Snyder SH.Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion[J].Proc Natl Acad Sci USA,1999,96:13978-13982.
  • 3Gabriele C,Antonio M,Emidio C,et al.Modeling of poly(ADP-ribose) polymerase (PARP) inhibitors.Docking of ligands and quantitative structure-activity relationship analysis[J].J Med Chem,2001,44:3786-3794.
  • 4Xu XJ,Hou TJ,Qiao XB,et al.Computer-Aided Drug Design (计算机辅助药物分子设计)[M].Beijing:Chemical Industry Press,2004:295.
  • 5Ferraris D,Ficco RP,Dain D,et al.Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.Part 4:Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries[J].Bioorg Med Chem,2003,11:3695-3707.
  • 6Ishida J,Hattori K,Yamamoto H,et al.4-Phenyl-1,2,3,6-tetrahydropyridine,an excellent fragment to improve the potency of PARP-1 inhibitors[J].Bioorg Med Chem Lett,2005,15:4221-4225.
  • 7Iwashitaa A,Hattorib K,Yamamoto H,et al.Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors[J].FEBS Lett,2005,579:1389-1393.
  • 8Steinhagen H,Gerisch M,Mittendorf J,et al.Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)[J].Bioorg Med Chem Lett,2002,12:3187-3190.
  • 9Jagtap PG,Southan GJ,Baloglu E,et al.The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones:potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)[J].Bioorg Med Chem Lett,2004,14:81-85.
  • 10Loh VM,Cockcroft X,Dillon KJ,et al.Phthalazinones.Part 1:the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose) polymerase[J].Bioorg Med Chem Lett,2005,15:2235-2238.

共引文献2

同被引文献25

  • 1张文婷,鄢浩,姜凤超.聚腺苷二磷酸核糖聚合酶-1抑制剂药效团模型的建立[J].药学学报,2007,42(3):279-285. 被引量:3
  • 2Hassa P O, Hottiger M O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribosepolymerases [ J ]. Front Biosci, 2008, 13 (4) : 3046 - 3082.
  • 3Peralta-leal A, Rodrguez-vargas J M, Aguilar-quesada R, et al. PARP inhibitors:New partners in the therapy of cancer and inflammatory diseases [ J ]. Free Radie Biol Med ,2009,47( 1 ) : 13 - 26.
  • 4Shalinsky D R, Donawho C K, Los G, et al. Preclini- cal Chemosensitization by PARP Inhibitors. In PARP Inhibitors for Cancer [ M ]. New York : Humana Press, 2015:225 - 260.
  • 5Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treat- ment of cancers deficient in DNA double-strand break repair[ J]. J Clin Oncol,2008,26(22) :3785 - 3790.
  • 6Johnson P. Olaparib recommendations for ovarian canc- er patients[J]. Futare Oncology,2015,12(2) :149 - 151.
  • 7Curtin N J. Poly ( ADP-ribose ) polymerase (PARP) and PARP inhibitors[ J]. Drug Discov Today Dis Mod- els,2012,9(2) :e51 - e58.
  • 8Krishnakumar R, Kraus W L. The PARP side of the nucleus : Molecular actions, physiological outcomes, and clinical targets[ J]. Mol Cell 2010,39( 1 ) :8 - 24.
  • 9Langelier M F, Pascal J M. PARP-1 mechanism for coupling DNA damage detection to poly (ADP-ribose) synthesis [ J ]. Curr Opin Struct Biol, 2013,23 ( 1 ) : 134 - 143.
  • 10Curtin N J. DNA repair dysregulation from cancer driver to therapeutic target [ J ]. Nat Rev Cancer, 2012,12(12) :801 - 817.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部